VITALITY BIOPHARMA ANNOUNCES EFFECTIVE S-1 REGISTRATION STATEMENT AND DTC ELIGIBILITY

CLEVELAND, OHIO – (September 2, 2021) – Vitality Biopharma, Inc. (OTC Mkts: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic powers of cannabinoids, today announced that the Securities and Exchange Commission has declared the Company’s Form S-1 registration statement effective. The registration statement was filed pursuant to the...

VITALITY BIOPHARMA ENTERS INTO $5 MILLION EQUITY FINANCING RELATIONSHIP WITH INSTITUTIONAL INVESTOR

CLEVELAND, OHIO – (August 20, 2021) – Vitality Biopharma, Inc. (VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic powers of cannabinoids, today announced that the Company had entered into a definitive agreement with an institutional investor for a $5,000,000 equity financing. Under the terms of the equity financing,...

FDA GRANTS VITALITY BIOPHARMA ORPHAN DRUG DESIGNATION FOR VBX-100 PRODRUG

CLEVELAND, OHIO – (August 10, 2021) – Vitality Biopharma, Inc. (OTC: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic powers of cannabinoids, today announced that the U.S. Food and Drug Administration (“FDA”) granted Orphan Drug Designation to its glycosylated cannabinoid prodrug VBX-100 for the treatment of pediatric ulcerative...

CEO Letter to Shareholders

To the Shareholders of Vitality Biopharma, Inc.:   In October 2018, Vitality raised $8.5 million of financing to advance its drug development program and acquire a Beverly Hills-based addiction clinic with the strategy of converting it into a cannabis-based treatment center for opioid dependent patients. Two weeks after the closing of this financing transaction and...

Vitality Biopharma Retains DelMorgan & Co. to Explore Strategic Alternatives

CLEVELAND, OHIO – (September 25, 2020) – Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”), a drug development company dedicated to unlocking the unique therapeutic powers of cannabinoids, today announced that it has retained DelMorgan & Co., an internationally recognized investment banking firm, to advise Vitality on its strategic alternatives, including potential financings, asset...

Vitality Biopharma Board Update

CLEVELAND, OHIO – (April 27, 2020)— Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, today announced that Dr. Anthony Maida has decided to resign from its Board of Directors. Dr. Maida had served on Vitality’s Board of Directors since 2012 and had...

Vitality Biopharma Welcomes New Executive Management Team

– Appointment of Current Director Michael Cavanaugh as Interim Chief Executive Officer – – Promotion of Current Controller and Counsel Richard McKilligan to Chief Financial Officer – LOS ANGELES, CA (MARKETWIRED – May 14, 2019) – Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals,...

Vitality Biopharma Co-Founder Dr. Avtar Dhillon Resigns from Board of Directors

LOS ANGELES, CA – (April 25, 2019) — Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that Dr. Avtar Dhillon has decided to resign...

Vitality Biopharma Appoints Former Ohio Governor Richard F. Celeste to Board

LOS ANGELES, Jan. 24, 2019 — Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, is pleased to announce that it has added an additional position on...

Vitality Biopharma to Present at the 11th Annual LD Micro Main Event

LOS ANGELES, CA – (GLOBE NEWSWIRE – December 3, 2018) — Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will be presenting at the...